Small-cell lung cancer (SCLC) remains an aggressive cancer with short-term survival due to limited therapeutic options. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor-2. This study aimed to investigate the efficacy and safety of apatinib in patients with extensive-stage (EC) SCLC who had progressed after two or three previous therapies.
Eligible patients were histologically confirmed ES-SCLC after two or three previous treatments, including a platinum-based regimen. Patients received apatinib at an initial dose of 500 mg once daily. The primary endpoint was the objective response rate.
Forty patients were enrolled. At the data cut-off time (November 15, 2018), the median follow-up was 7.4 months; no patients remained on treatment, and five were still in follow-up. An objective response was achieved in 7 of 40 patients (17.5%) in the intention-to-treat population, and 7 of 38 patients (18.4%) in the per-protocol population. The median progression-free survival and overall survival were 3.0 months and 5·8 months, respectively. The most commonly observed grade 3 or greater treatment-related adverse events were hypertension, hand–foot syndrome, increased L-gamma-glutamyltransferase.
Apatinib exhibited efficacy and an acceptable safety profile in previously heavily-treated ES-SCLC patients. Further exploration of apatinib in phase III trials is warranted.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $35.17 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Bishop, K., Kosary, C. L. et al. SEER Cancer Statistics Review, 1975-2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. (National Cancer Institute, Bethesda, MD, 2017).
Jett, J. R., Schild, S. E., Kesler, K. A. & Kalemkerian, G. P. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143, e400S–e419S (2013).
Byers, L. A. & Rudin, C. M. Small cell lung cancer: where do we go from here? Cancer 121, 664–672 (2015).
Asai, N., Ohkuni, Y., Kaneko, N., Yamaguchi, E. & Kubo, A. Relapsed small cell lung cancer: treatment options and latest developments. Ther. Adv. Med. Oncol. 6, 69–82 (2014).
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M. et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385, 36–42 (2015).
Hanna, N., Bunn, P. A. Jr, Langer, C., Einhorn, L., Guthrie, T. Jr, Beck, T. et al. Randomized phase III trial comparing rinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 24, 2038–2043 (2006).
Zatloukal, P., Cardenal, F., Szczesna, A., Gorbunova, V., Moiseyenko, V., Zhang, X. et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann. Oncol. 21, 1810–1816 (2010).
Horita, N., Yamamoto, M., Sato, T., Tsukahara, T., Nagakura, H., Tashiro, K. et al. Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients. Sci. Rep. 5, 15437 (2015).
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P. et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17, 883–895 (2016).
Lucchi, M., Mussi, A., Fontanini, G., Faviana, P., Ribechini, A. & Angeletti, C. A. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur. J. Cardiothorac. Surg. 21, 1105–1110 (2002).
Salven, P., Ruotsalainen, T., Mattson, K. & Joensuu, H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J. Cancer 79, 144–146 (1998).
Zhan, P., Wang, J., Lv, X. J., Wang, Q., Qiu, L. X., Lin, X. Q. et al. Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J. Thorac. Oncol. 4, 1094–1103 (2009).
Litz, J., Sakuntala Warshamana-Greene, G., Sulanke, G., Lipson, K. E. & Krystal, G. W. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46, 283–291 (2004).
Tanno, S., Ohsaki, Y., Nakanishi, K., Toyoshima, E. & Kikuchi, K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46, 11–19 (2004).
Horn, L., Dahlberg, S. E., Sandler, A. B., Dowlati, A., Moore, D. F., Murren, J. R. et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J. Clin. Oncol. 27, 6006–6011 (2009).
Spigel, D. R., Townley, P. M., Waterhouse, D. M., Fang, L., Adiguzel, I., Huang, J. E. et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J. Clin. Oncol. 29, 2215–2222 (2011).
Pujol, J. L., Lavole, A., Quoix, E., Molinier, O., Souquet, P. J., Barlesi, F. et al. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†. Ann. Oncol. 26, 908–914 (2015).
Tiseo, M., Boni, L., Ambrosio, F., Camerini, A., Baldini, E., Cinieri, S. et al. Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J. Clin. Oncol. 35, 1281–1287 (2017).
Ready, N. E., Pang, H. H., Gu, L., Otterson, G. A., Thomas, S. P., Miller, A. A. et al. Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: a randomized, double-blind, placebo-controlled phase II study-CALGB 30504 (Alliance). J. Clin. Oncol. 33, 1660–1665 (2015).
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220–2229 (2018).
Lan, C. Y., Wang, Y., Xiong, Y., Li, J. D., Shen, J. X., Li, Y. F. et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. Lancet Oncol. 19, 1239–1246 (2018).
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y. et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J. Clin. Oncol. 34, 1448–1454 (2016).
Li, J., Qin, S., Xu, J., Guo, W., Xiong, J., Bai, Y. et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol. 31, 3219–3225 (2013).
Yan, X., Wang, Q., Wang, H., Li, P., Zhang, G., Zhang, M. et al. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. J. Cancer Res. Clin. Oncol. 145, 235–340 (2019).
Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1–10 (1989).
O’Brien, M. E., Ciuleanu, T. E., Tsekov, H., Shparyk, Y., Cuceviá, B., Juhasz, G. et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J. Clin. Oncol. 24, 5441–5447 (2006).
de Jong, W. K., ten Hacken, N. H. & Groen, H. J. Third-line chemotherapy for small cell lung cancer. Lung Cancer 52, 339–342 (2006).
Park, S., Ahn, M. J., Ahn, J. S., Lee, J., Hong, Y. S., Park, B. B. et al. Combination chemotherapy with paclitaxel and ifosfamide as the third-line regimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 58, 116–122 (2007).
Lebeau, B., Chouaïd, C., Baud, M., Masanès, M. J. & Febvre, M. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer. Lung Cancer 67, 188–193 (2010).
Simos, D., Sajjady, G., Sergi, M., Liew, M. S., Califano, R., Ho, C. et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin. Lung Cancer 15, 110–118 (2014).
Coutinho, A. D., Shah, M., Lunacsek, O. E., Eaddy, M. & Willey, J. P. Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy. Lung Cancer 127, 53–58 (2019).
Spigel, D. R., Waterhouse, D. M., Lane, S., Legenne, P. & Bhatt, K. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Clin. Lung Cancer 14, 356–363 (2013).
Allen, J. W., Moon, J., Redman, M., Gadgeel, S. M., Kelly, K., Mack, P. C. et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J. Clin. Oncol. 32, 2463–2470 (2014).
Jiang, T., Chu, Q., Wang, H., Zhou, F., Gao, G., Chen, X. et al. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int. J. Cancer 144, 2605–2612 (2019).
Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassará, A., Wyser Rmili, C., Kiialainen, A. et al. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Sci. Transl. Med. 9, pii: eaak9670 (2017).
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T. et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544, 250–254 (2017).
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C. et al. Low-dose apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer. Cancer Immunol. Res. 7, 630–643 (2019).
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R. et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin. Cancer Res. 25, 515–523 (2019).
We thank the patients and their families who participated in this study, and we also thank Jiangsu Hengrui Pharmaceuticals Co. for providing apatinib.
Y.F., Y.-J.X., Z.-Y.H., H.-Y.L., X.-M.Y., L.G., K.-Y.C., J.Q., X.-L.X., J.Z., X.S., Y.J., N.H., F.-J.X., Y.-P.L., J.C. and W.-F.L. recruited patients for the study, collected, analysed and interpreted the data. Y.F., Y.-J.X. and Z.-Y.H. designed the study, tables and figures. P.Z. analysed and interpreted the data and designed the figures and tables. M.C. designed the study. W.-Z.X. analysed and interpreted the data. Development of the first draft was performed by Y.F. and Y.-J.X. All authors provided final approval to submit for publication.
The authors declare no competing interests.
Ethics approval and consent to participate
This study was approved by Medical Ethics Committee of Zhejiang Cancer Hospital with the committee’s reference number: IRB-2016-124. The study was performed in accordance with the Declaration of Helsinki. All enrolled patients provided written informed consent before any study-specific procedures were performed.
This is investigator initiated trial and Jiangsu Hengrui Pharmaceuticals Company provided apatinib for this study, but was not involved in the study design, data collection, analysis and interpretation, article writing, or the decision to submit for publication. All authors had full access to raw data, and the corresponding author has final responsibility for the publication submission.
All data included in this study are available upon request by contact with the corresponding author.
Note: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.